The firm has multiple catalysts that could generate a rally of 35% for the stock.
The firm has multiple catalysts that could generate a rally of 35% for the stock.
Semiconductor stocks are trading in a pattern they traced before the dot-com bubble burst. But there are signs that the industry is still growing.
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
Several catalysts are on the calendar for semiconductor companies.
The company has quietly transformed its operations. The stock is a buy.
The stock has done well so far while not yet reflecting the larger growth story.
Higher-quality cyclicals could perform solidly even if the economy goes into recession.
Technology stocks are approaching their peak as a portion of the S&P 500, which could portend some rough months ahead.
Neurocrine Biosciences has retreated from its all-time high, creating a buying opportunity for the next phase of growth.
The stock has underperformed since Barron’s picked it in June 2025.
The picture could turn around for banks, which have struggled lately.
Investors see potential pitfalls for consumer stocks. Shop for those that are showing signs of stabilizing.
The company’s recent results paint a picture of a business positioning itself to generate cash for shareholders.
Armstrong stock has been hit by concerns about tighter spending in the construction sector. Those worries are overblown.
Growth stocks have been down for months, but there are signals that it’s time for them to move higher again.
Its growth outlook has improved. Technicals also speak to higher prices.
The stock market typically takes a hit in early fall. We like two sector ETFs whose September dips are regularly bested by their bigger rises in October.
The stock’s growth story remains intact. We still like the pick.
Utility stocks have been hit by rising Treasury yields and data-center backlash, but valuations are low and earnings growth remains strong.
Moderna’s stock has doubled this week. There are better buys out there now.
of 133 pages